Instructions for Xefocam (Lornoxicam) lyophilisate Vial 8 mg
English product name
Xefocam
Release form
lyophilizate d/r-ra d/v/v and b/m of introduction 8 mg: fl 5 pcs.
Description:
Lyophilizate for preparation of solution for injection into/into and/or into/out as a dense mass of yellow; The reduced solution is a clear yellow solution.
1 fl
Lornoxicam 8 mg*
* The amount of Lornoxicam, including an excess of 7.5%, is 8.6 mg.
Auxiliary substances: mannitol - 100 mg, tromethamol - 12 mg, dynatria edetat - 0.2 mg.
Dark glass bottles (5) - cardboard packs.
Dark glass bottles (5) - plastic trays (1) - cardboard packs.
ATC codes
M01AC05 Lornoxicam
Clinical-pharmacological groups / Group affiliation
NAPS
Active substance Xefocam
Lornoxicam
Pharmacotherapy group
NSAIDs
Storage Conditions Xefocam
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date Lornoxicam
The shelf life is three years. Do not apply after expiry date.
Use the prepared solution for 24 hours.
Testimony Xefocam:
- short-term treatment of mild to moderate acute pain syndrome;
- symptomatic therapy of pain and inflammation against osteoarthritis;
- symptomatic therapy of pain and inflammation against rheumatoid arthritis.
Method of use, course and dosage:
The drug is used parenterally.
The injection solution is prepared immediately prior to use by dissolving the contents of one vial (8 mg of lornoxicam) with injection water (2 ml). After the solution is prepared, the needle is replaced.
The solution thus prepared is introduced into/into or into/into the post-operative pains and into/into acute seizure of lumbago/scialgia.
B/m injections are made with a long needle.
The duration of the solution in/out shall not be less than fifty seconds, in/m - not less than five seconds.
The recommended single dose is 8 mg b/w or b/m. Daily dose should not exceed 16 mg. Some patients may require an additional dose of 8 mg for the first 24 hours.
A minimum effective dose should be applied at the lowest possible short course.
Lornoxicam is not intended for use in children and adolescents under the age of 18, as there is insufficient data on its safety and effectiveness.
It is not necessary to select a dose for elderly patients (over 65 years of age) if there is no disorder of the kidney or liver function. The drug should be prescribed with caution, because in this age group, unwanted effects from the gastrointestinal tract are worse.
Patients with mild to moderate kidney dysfunction may require a dose correction.
Patients with moderate liver dysfunction may require a dose correction.
Undesirable effects can be minimized by using the lowest effective dose of the drug for the shortest amount of time necessary to control symptoms.
Application for kidney disorders
The use of the preparation is contraindicated in the case of severe renal insufficiency (serum creatinine level greater than 700 mkmol/l), progressive kidney diseases confirmed by hyperkalaemia.
Patients with mild to moderate kidney dysfunction may require a dose correction.
Use in liver disorders Xefocam
The use of the preparation in severe liver failure is contraindicated.
Patients with moderate liver dysfunction may require a dose correction.
Terms of Sale Xefocam
The drug is prescription.
Application in elderly patients
Elderly patients (over 65 years of age) should be administered with caution.
Use in children
It is contraindicated in children and adolescents under 18 years of age.
- Nosology Xefocam (ICD codes)
- M05
- Seropositive rheumatoid arthritis
- M15
- Polyarthrosis
- M19.9
- Arthrosis unspecified
- M25.5
- Joint pain
- R52.0
- Acute pain
Pharmacological effect Xefocam:
NSAIDs are classified as oxycams. It has a pronounced analgesic and anti-inflammatory effect.
The mechanism of action is the suppression of prostaglandin synthesis (inhibition of the enzyme COX), leading to the suppression of inflammation.
Lornoxicam does not affect the basic indicators of the body: Body temperature, HSS, AD, ECG data, spirometry.
The analgesic effect of Lornoxicam is not related to narcotic action.
The drug Xefocam does not have an opiate-like effect on the CNS and, unlike narcotic analgesics, does not suppress breathing, does not cause drug dependence.
Due to the presence of a local irritant effect on the gastrointestinal tract and systemic ulcerogenic effect associated with the suppression of prostaglandin synthesis, complications from the gastrointestinal tract are frequent undesirable effects in the treatment of NSAIDs.
